890 assets in Neoplasm

Therapeutic assets addressing Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
ibr854 cell Neoplasm	Imbioray (Hangzhou) Biomedicine Co., Ltd.	P1	CC (40)
imm01 Neoplasm	ImmuneOnco Biopharmaceuticals (Shanghai) Inc.	P1/2	CC (40)
Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Met (Met Proto-Oncogene, Hepatocyte Growth Factor (Hgf) Receptor, Hgfr, Scatter Factor (Sf) Receptor, Hgf/Sf Receptor, Receptor Tyrosine-Protein Kinase C-Met, Papillary Renal Cell Carcinoma 2, Rccp2)] And Anti-[Homo Sapiens Egfr (Epidermal Growth Factor Receptor, Receptor Tyrosine-Protein Kinase Erbb-1, Erbb1, Her1, Her-1, Erbb)], Homo Sapiens Monoclonal Antibody, Bispecific Neoplasm	Betta Pharmaceuticals Co., Ltd.	P1/2	CC (40)
imp9064 Neoplasm	Impact Therapeutics, Inc.	P1/2	CC (40)
Inbrx-106 Neoplasm	Inhibrx Biosciences, Inc	P1/2	CC (40)
Interleukin 18 (Recombinant Human Mutein Clone St-067) Neoplasm	Simcha IL-18, Inc.	P1/2	CC (40)
INX315 Neoplasm	Incyclix Bio	P1/2	CC (40)
ipg1094 Neoplasm	Nanjing Immunophage Biotech Co., Ltd	P1/2	CC (40)
ipn01194 Neoplasm	Ipsen	P1/2	CC (40)
Ixovex-1 Neoplasm	Psivac Ltd	P1/2	CC (40)
Jnj-64619178 Neoplasm	Janssen Research & Development, LLC	P1	CC (40)
Jnj-70218902 Neoplasm	Janssen Research & Development, LLC	P1	CC (40)
Jnj-78306358 Neoplasm	Janssen Research & Development, LLC	P1	CC (40)
js207 Neoplasm	Mabwell (Shanghai) Bioscience Co., Ltd.	P1/2	CC (40)
kt-333 Neoplasm	Kymera Therapeutics, Inc.	P1	CC (40)
Limertinib Neoplasm	Innovent Biologics (Suzhou) Co. Ltd.	P1/2	CC (40)
Mdna11 Neoplasm	Medicenna Therapeutics, Inc.	P1/2	CC (40)
mk-4464 Neoplasm	Merck Sharp & Dohme LLC	P1	CC (40)
Muzastotug Neoplasm	Sanofi	P1/2	CC (40)
Necvax-Neo1 Neoplasm	NEC Bio B.V	P1/2	CC (40)
Omx-0407 Neoplasm	iOmx Therapeutics AG	P1/2	CC (40)
Otx-2002 Neoplasm	Omega Therapeutics	P1/2	CC (40)
Pexmetinib Neoplasm	Dan Zandberg	P1/2	CC (40)
Prednisolone Neoplasm	Eisai Inc.	P1/2	CC (40)
Prs-344 Neoplasm	Servier Bio-Innovation LLC	P1/2	CC (40)
Pucotenlimab Neoplasm	Binhui Biopharmaceutical Co., Ltd.	P1/2	CC (40)
ql1203 Neoplasm	Qilu Pharmaceutical Co., Ltd.	P1/2	CC (40)
ql2107 Neoplasm	Qilu Pharmaceutical Co., Ltd.	P1/2	CC (40)
qls31905 Neoplasm	Qilu Pharmaceutical Co., Ltd.	P1/2	CC (40)
rc148 Neoplasm	RemeGen Co., Ltd.	P1/2	CC (40)
rs-0139 Neoplasm	RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S.	P1	CC (40)
Rx-Af01 Neoplasm	Sun Yat-sen University	P1/2	CC (40)
S095012 Neoplasm	Servier Bio-Innovation LLC	P1/2	CC (40)
s241656 Neoplasm	Institut de Recherches Internationales Servier	P1/2	CC (40)
sa53-os Neoplasm	Lamassu Bio Inc	P1/2	CC (40)
sar445877 Neoplasm	Sanofi	P1/2	CC (40)
sb-4826 Neoplasm	University of California, San Diego	P1/2	CC (40)
Shr-7367 Neoplasm	Shanghai Hengrui Pharmaceutical Co., Ltd.	P1/2	CC (40)
Shr-9839 For Neoplasm	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	P1/2	CC (40)
smp3124lp Neoplasm	Sumitomo Pharma America, Inc.	P1/2	CC (40)
Stc-15 Neoplasm	STORM Therapeutics LTD	P1/2	CC (40)
t3011 Neoplasm	ImmVira Pharma Co. Ltd	P1/2	CC (40)
Ter-2013 Neoplasm	Terremoto Biosciences Inc.	P1/2	CC (40)
Test Product Hy0001A For Neoplasm	Sichuan Huiyu Pharmaceutical Co., Ltd	P1/2	CC (40)
Test Product Hyp-6589 Neoplasm	Sichuan Huiyu Pharmaceutical Co., Ltd	P1/2	CC (40)
th9619 Neoplasm	One-carbon Therapeutics AB	P1/2	CC (40)
Tipiracil Neoplasm	Parabilis Medicines, Inc.	P1/2	CC (40)
tng456 Neoplasm	Tango Therapeutics, Inc.	P1/2	CC (40)
Trifluridine Neoplasm	Parabilis Medicines, Inc.	P1/2	CC (40)
Tsr-033 Neoplasm	Tesaro, Inc.	P1	CC (40)

Showing 451 to 500 of 889 assets

PreviousPage 10 of 18Next